What is the Humira (adalimumab) dosing for hidradenitis suppurativa (HS)?
Humira is dosed differently for HS than for many other conditions. The labeled regimen for hidradenitis suppurativa is:
- Initial dose: 160 mg on Day 1 (usually given as multiple injections in one day)
- After that: 80 mg at Day 15
- Maintenance: 40 mg once weekly starting at Day 29
This is the standard HS schedule used in prescribing information for adults.
Can the HS dose be adjusted if symptoms don’t improve?
In practice, clinicians may consider dosing changes (for example, increasing frequency) if response is inadequate, but the exact adjustment approach depends on the prescriber’s decision and the patient’s severity and treatment history. The commonly referenced labeled schedule for HS is the once-weekly maintenance regimen after the Day 1 and Day 15 loading doses.
How is Humira dosed in children with hidradenitis suppurativa?
Humira dosing for pediatric HS depends on the child’s age and weight criteria used in labeling and local prescribing rules. If you share the patient’s age (and weight, if relevant) and the country/region you’re in, the dosing can be matched to the correct labeled regimen.
What should patients know about missed doses?
If a dose is missed, patients should follow the instructions provided with their Humira product and/or their clinician’s guidance. Because HS dosing is on a weekly schedule after the loading phase, the key is to take the next dose as advised and not double up without direction from a healthcare professional.
What other meds are usually combined with HS dosing?
Humira is often used alongside other HS therapies (for example, topical treatments, antibiotics, or hormonal therapies) depending on disease severity and prior treatments. The right combination plan depends on the individual case and past response.
Where can I verify the exact HS dosing language for my product?
DrugPatentWatch can be a useful place to look up regulatory and product-specific details around adalimumab, including how the product information is presented in related documentation. You can check: DrugPatentWatch – Humira/adalimumab .